" "
Home > Journals > Ophthalmology and Allied Sciences

Ophthalmology and Allied Sciences

Submit your article Read this Journals View all journals
Full Text (PDF)
Original Article

Efficacy and Safety of Timolol 0.5% Versus Brimonidine 0.2% in Lowering IOP in Cases of Primary Open Angle Glaucoma

Sharanabasamma M.* , Sharanabasamma M.* , Vaibhav K.**

Author Information
Licence:


Ophthalmology and Allied Sciences 2(1):p 21-26, . | DOI: DOI: http://dx.doi.org/10.21088/oas.2454.7816.2116.5
How Cite This Article:
Received : N/A         Accepted : N/A          Published : N/A
Abstract

 Aims: To compare the efficacy and safety of Timolol maleate 0.5% and Brimonidine 0.2% in lowering IOP in cases of Primary Open Angle Glaucoma. Settings and Design: A single center randomized clinical trial was conducted in which the clinical outcome (efficacy) and safety profile of twice daily brimonidine tartarate 0.2% were compared with those of Timolol maleate 0.5% in patients with POAG for one year between November 2013 to October 2014. Materials and Method: Fifty patients were enrolled, twenty five in the Brimonidine group and twenty five in the Timolol group. Patients used drugs twice daily for five weeks, and were followed up at baseline visit and at weeks three and five. Clinical success meant reduction of intraocular pressure (IOP), Data about safety and adverse events were analyzed. Statistical Analysis Used: Student test. Results: Both drugs showed sustained ocular hypotensive efficacy in the study period of one year. At baseline the mean IOP was 24.34 ± 2.82 mm Hg in the timolol group and 24.16 ± 2.76 mm Hg in the brimonidine group. The IOP readings after treatment at 3rd and 5th week were significantly lower in both groups (P < 0.001) with no significant statistical difference between the two groups. 20% of the patients in Timolol group and 8% of patients in Brimonidine group, reported mild adverse events. Conclusions: Both the drugs have same efficacy and safety profile.

Keywords: Brimonidine; Glaucoma; Timolol.

References

No records found.

Funding

Author Information

Authors and Affiliatione

  • Sharanabasamma M.*
    ,
  • Sharanabasamma M.*
    ,
  • Vaibhav K.**
    ,
Conflicts of Interest
Supplementary Information

Below is the link to the supplementary material.

Rights and Permissions


About this article

Cite this article

Licence:


Download citation

Received Accepted Published
N/A N/A N/A
DOI: DOI: http://dx.doi.org/10.21088/oas.2454.7816.2116.5
Keywords

Article Level Metrics

Last Updated

Sunday 08 June 2025, 16:13:22 (IST)

4

Accesses

00
0
00

Citations


22
11
23

View full article metrics including social shares, article views and publishing history


Article Keywords

Keyword Highlighting

Highlight selected keywords in the article text.


Timeline

Received N/A
Accepted N/A
Published N/A

licence




Access this article


Reprint Order Form
Buy Single Article
Institutional Subscriptions

Share